The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Beta Blockers and Breast Cancer Mortality: A Population- Based Study
Abstract
Purpose: Preclinical studies have demonstrated that antagonism of β 2 -adrenergic signaling inhibits several pathways necessary for breast tumor progression and metastasis. A series of population-based observational studies were conducted to examine associations between beta blocker use and breast tumor characteristics at diagnosis or breast cancer–specific mortality. Patients and Methods: Linked national cancer registry and prescription dispensing data were used to identify women with a diagnosis of stage I to IV invasive breast cancer between January 1, 2001, and December 31, 2006. Women taking propranolol (β 1 /β 2 antagonist; n = 70) or atenolol (β 1 antagonist; n = 525), in the year before breast cancer diagnosis were matched (1:2) to women not taking a beta blocker (n = 4,738). Associations between use of propranolol or atenolol and risk of local tumor invasion at diagnosis (T4 tumor), nodal or metastatic involvement at diagnosis (N2/N3/M1 tumor), and time to breast cancer–specific mortality were assessed. Results: Propranolol users were significantly less likely to present with a T4 (odds ratio [OR], 0.24, 95% CI, 0.07 to 0.85) or N2/N3/M1 (OR, 0.20; 95% CI, 0.04 to 0.88) tumor compared with matched nonusers. The cumulative probability of breast cancer–specific mortality was significantly lower for propranolol users compared with matched nonusers (hazard ratio, 0.19; 95% CI, 0.06 to 0.60). There was no difference in T4 or N2/N3/M1 tumor incidence or breast cancer–specific mortality between atenolol users and matched nonusers. Conclusion: The results provide evidence in humans to support preclinical observations suggesting that inhibiting the β 2 -adrenergic signaling pathway can reduce breast cancer progression and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,379
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686 · cited 1×
“invasion and migration, key steps in tumor progression and the pathogenesis of metastasis.(6-15) Norepi-”
BackgroundAJCC Cancer Staging Manual. 6th ed
Greene, F., Page, D., Id, F., Fritz, J., Balch, C., & Haller, D. (2002) · Cited by 2,324
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Lu, C., Jennings, N. B., Armaiz-Pena, G., Bankson, J. A., Ravoori, M., et al. (2006) · Nature Medicine · doi:10.1038/nm1447 · Cited by 1,320 · cited 4×
“These include the promotion of tumor cell invasion and migration,(8-10) the regulation of immune responses to tumor cells,(16) the inhibition of apoptosis,(17,18) and the induction of vascular endothelial growth factor expression.(13) It has been shown that these effects are mediated through several downstream signali…”
BackgroundInfluentialThe influence of bio-behavioural factors on tumour biology: pathways and mechanisms
Antoni, M. H., Lutgendorf, S. K., Cole, S. W., Dhabhar, F. S., Sephton, S. E., McDonald, P. G., Stefanek, M., & Sood, A. K. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1820 · Cited by 981
The sympathetic nervous system induces a metastatic switch in primary breast cancer
Sloan, E. K., Priceman, S. J., Cox, B. F., Yu, S., Pimentel, M. A., Tangkanangnukul, V., Arevalo, J. M. G., Morizono, K., Karanikolas, B. D. W., Wu, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0522 · Cited by 930 · cited 4×
“receptor, and are inhibited by 2 receptor antagonists (eg, propranolol).(8-12,15,16,20) Similar inhibitory effects are not observed with the use of 1 selective antagonists (eg, atenolol).”
BackgroundResultInfluentialSchneeweiss, S. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.9.854 · Cited by 711
Macleod, U., Mitchell, E. D., Burgess, C., Macdonald, S., & Ramirez, A. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605398 · Cited by 525
Factors predicting delayed presentation of symptomatic breast cancer: a systematic review
Ramirez, A., Westcombe, A., Burgess, C., Sutton, S., Littlejohns, P., & Richards, M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02142-x · Cited by 493
Stress hormone-mediated invasion of ovarian cancer cells
Sood, A. K., Bhatty, R., Kamat, A. A., Landen, C. N., Han, L., Thaker, P. H., Li, Y., Gershenson, D. M., Lutgendorf, S., & Cole, S. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1698 · Cited by 491
Powe, D. G., Voss, M. J., Zänker, K. S., Habashy, H. O., Green, A. R., Ellis, I. O., & Entschladen, F. (2010) · Oncotarget · doi:10.18632/oncotarget.197 · Cited by 453
Yang, E. V., Sood, A. K., Chen, M., Li, Y., Eubank, T. D., Marsh, C. B., Jewell, S., Flavahan, N. A., Morrison, C., Yeh, P.-E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2496 · Cited by 407
Brookhart, M. A., Patrick, A. R., Dormuth, C., Avorn, J., Shrank, W., Cadarette, S. M., & Solomon, D. H. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm070 · Cited by 381
Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters
Entschladen, F., Drell, T. L., Lang, K., Joseph, J., & Zaenker, K. S. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01431-7 · Cited by 334
Lutgendorf, S. K., Cole, S. W., Costanzo, E. S., Bradley, S., Coffin, J. E., Jabbari, S., Rainwater, K. K., Ritchie, J. M., Yang, M., & Sood, A. K. (2003) · PubMed · Cited by 330
Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers.
Masur, K., Niggemann, B., Zänker, K. S., & Entschladen, F. (2001) · PubMed · Cited by 308
Palm, D., Lang, K., Niggemann, B., Drell, T. L., Masur, K., Zaenker, K. S., & Entschladen, F. (2006) · International Journal of Cancer · doi:10.1002/ijc.21723 · Cited by 298
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis
Sood, A. K., Armaiz-Pena, G. N., Halder, J., Nick, A. M., Stone, R. L., Hu, W., Carroll, A. R., Spannuth, W. A., Deavers, M. T., Allen, J. K., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40802 · Cited by 283
Benish, M., Bartal, I., Goldfarb, Y., Levi, B., Avraham, R., Raz, A., & Ben-Eliyahu, S. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9890-5 · Cited by 281
Early discontinuation of tamoxifen: A Lesson for oncologists
Barron, T. I., Connolly, R., Bennett, K., Feely, J., & Kennedy, M. J. (2007) · Cancer · doi:10.1002/cncr.22485 · Cited by 279
Self-citationDrell, T. L., Joseph, J., Lang, K., Niggemann, B., Zaenker, K. S., & Entschladen, F. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024491219366 · Cited by 277
Lang, K., Drell, T. L., Lindecke, A., Niggemann, B., Kaltschmidt, C., Zaenker, K. S., & Entschladen, F. (2004) · International Journal of Cancer · doi:10.1002/ijc.20410 · Cited by 256
Host Factors and Cancer Progression: Biobehavioral Signaling Pathways and Interventions
Lutgendorf, S. K., Sood, A. K., & Antoni, M. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9357 · Cited by 237
Sastry, K. S. R., Karpova, Y., Prokopovich, S., Smith, A. J., Essau, B., Gersappe, A., Carson, J. P., Weber, M. J., Register, T. C., Chen, Y. Q., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611370200 · Cited by 229
Zhang, D., Yong Ma, Q., Hu, H.-T., & Zhang, M. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.1.11944 · Cited by 195
Neuroendocrine modulation of cancer progression
Armaiz-Peña, G. N., Lutgendorf, S. K., Cole, S. W., & Sood, A. K. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2008.06.007 · Cited by 161
The Neuroendocrine Impact of Chronic Stress on Cancer
Thaker, P. H., Lutgendorf, S. K., & Sood, A. K. (2007) · Cell Cycle · doi:10.4161/cc.6.4.3829 · Cited by 152
Stress-related modulation of matrix metalloproteinase expression
Yang, E. V., Bane, C. M. H., MacCallum, R. C., Kiecolt‐Glaser, J. K., Malarkey, W. B., & Glaser, R. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00270-9 · Cited by 132
Li, C. I., Malone, K. E., Weiss, N. S., Boudreau, D. M., Cushing‐Haugen, K. L., & Daling, J. R. (2003) · Cancer · doi:10.1002/cncr.11663 · Cited by 130
Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers, and Breast Cancer
Meier, C. R., Derby, L. E., Jick, S. S., & Jick, H. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.3.349 · Cited by 116
Long‐term use of antihypertensive drugs and risk of cancer
Assimes, T. L., Elstein, E., Langleben, A., & Suissa, S. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1656 · Cited by 72
Cited by
Autonomic nerve development contributes to prostate cancer progression
Magnon, C., Hall, S. J., Lin, J., Xue, X., Gerber, L., Freedland, S. J., & Frenette, P. S. (2013) · Science · doi:10.1126/science.1236361 · Cited by 1,287
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 848
Molecular Pathways: Beta-Adrenergic Signaling in Cancer
Cole, S. W., & Sood, A. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0641 · Cited by 681
Sympathetic nervous system regulation of the tumour microenvironment
Cole, S. W., Nagaraja, A. S., Lutgendorf, S. K., Green, P. A., & Sood, A. K. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3978 · Cited by 576
Perioperative events influence cancer recurrence risk after surgery
Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B., & Sloan, E. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.194 · Cited by 556
Metadata
- Authors
- Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K., & Visvanathan, K.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-07-01
- Volume
- 29
- Issue
- 19
- Pages
- 2635-2644
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139731996
- Cited by
- 529
- References
- 32
- FWCI
- 23.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.